Format

Send to

Choose Destination
Acta Neuropsychiatr. 2018 Apr;30(2):111-116. doi: 10.1017/neu.2017.13. Epub 2017 May 8.

Investigation of serum levels of sortilin in response to antidepressant treatment.

Author information

1
1Translational Neuropsychiatry Unit,Department of Clinical Medicine,Aarhus University,Risskov,Denmark.
2
3The Lundbeck Foundation Research Center,MIND,Aarhus University,Aarhus,Denmark.
3
2The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH),Aarhus,Denmark.

Abstract

BACKGROUND:

The identification of biomarkers for depression is of great clinical relevance as the diagnosis is currently subjective. Recent research points towards sortilin as a potential biomarker for depression, and the aim of the current study was to investigate the serum sortilin level in response to antidepressant treatment.

METHODS:

The study included 56 depressed individuals of which 41 responded to treatment. Depression scores and serum levels of sortilin were measured at baseline and after 12 weeks of antidepressant treatment. Statistical analyses were performed using Stata 13.

RESULTS:

The depression score and response to treatment were not predicted by the sortilin level. Likewise, we observed no significant change in serum sortilin levels following 12 weeks of antidepressant treatment. Furthermore, no association between the serum sortilin level and depression score was observed.

CONCLUSION:

The results do not point towards sortilin as a state-dependent biomarker.

KEYWORDS:

antidepressant treatment; biomarker; depression; sortilin

PMID:
28478778
DOI:
10.1017/neu.2017.13

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center